Bovine papillomavirus cDNA and Antigen

Bovine papillomavirus (BPV) is a virus that infects cattle and causes papillomas, or warts, to develop on the skin and mucosal surfaces of infected animals. BPV is classified as a DNA virus and has a genome of approximately 8 kb in length. BPV is highly species-specific and does not infect humans or other species. BPV infections are common in cattle populations worldwide and are typically self-limiting, with the warts regressing and disappearing within 6-18 months. In rare cases, BPV infections can lead to the development of malignant tumors, such as squamous cell carcinomas. BPV is primarily spread through direct contact with infected animals or contaminated fomites, and control measures include maintaining biosecurity, testing, and culling infected animals, and the use of vaccines.

Bovine papillomavirus (BPV) antigen refers to a substance that is recognized by the immune system as foreign and triggers the production of antibodies. This antigen is found in BPV virus and can be used in laboratory tests to detect BPV infections in cattle. Detection of BPV antigen in skin or mucosal lesion samples, or in blood samples, can help diagnose BPV infections and monitor the effectiveness of vaccines against the virus. Different BPV antigens may be used to detect different forms of the virus, such as the structural proteins of the virus or the viral oncogenes. The presence of BPV antigens in a sample indicates that the animal is infected with BPV and can spread the virus to other animals.

Bovine papillomavirus (BPV) is a type of virus that can cause papillomas, which are benign skin tumors, in cattle. The virus has several genes, including E1, E2, E3, E4, E6, E7, and L1/L2.

E1 and E2 are involved in viral replication and transcription, respectively.
E3 and E4 are thought to play a role in the maintenance of the viral life cycle and in modulating the host immune response to the virus.
E6 and E7 are the main oncogenes of BPV, and they are responsible for the transformation of infected cells into cancerous cells. E6 and E7 target cellular proteins that regulate the cell cycle, promoting cell proliferation and inhibiting apoptosis (programmed cell death).
L1 and L2 are viral capsid proteins, which form the outer shell of the virus particle.
EB (early protein of bovine papillomavirus) is another term used to describe the E proteins of BPV.

By increasing our knowledge of BPV and its key proteins, we can continue to improve animal health and minimize the impact of this virus on cattle populations. Stay informed about the latest research on BPV and its impact on animal health.

Bovine papillomavirus (BPV) cDNA and recombinant antigens can be used to develop vaccines and diagnostic tests for the prevention and control of BPV-associated diseases. Vaccines made with BPV cDNA are more effective than traditional killed-virus vaccines, as they contain the entire genetic material of the virus, allowing for the full expression of protective antigens. Recombinant antigens can be used to develop diagnostic tests for the detection of BPV infection. These tests are more sensitive than traditional methods and can detect asymptomatic BPV infections. BPV cDNA and recombinant antigens can also be used to develop gene therapy treatments for BPV-associated diseases.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.